CAPLIPOINT.NS Profit & Loss
Caplin Point Laboratories Ltd.
Profit & Loss Balance Sheet Cash Flow
Profit & Loss · 4 years on file
(FY2022-23 to FY2025-26)
· fetched 2026-08-23 21:40
| Line item | FY2022-23 | FY2023-24 | FY2024-25 | FY2025-26 | Source (XBRL element) |
|---|---|---|---|---|---|
| Revenue from Operations | ₹1,466.73 Cr. | ₹1,694.10 Cr. | ₹1,937.47 Cr. | ₹2,187.19 Cr. | RevenueFromOperations |
| Gross Revenue (incl. inter-segment) | N/A | N/A | ₹2,033.90 Cr. | ₹2,302.73 Cr. | SegmentRevenueFromOperations |
| Other Income | ₹55.98 Cr. | ₹66.94 Cr. | ₹96.43 Cr. | ₹115.54 Cr. | OtherIncome |
| Total Income | ₹1,522.71 Cr. | ₹1,761.04 Cr. | ₹2,033.90 Cr. | ₹2,302.73 Cr. | Income |
| Cost of Materials Consumed | ₹223.04 Cr. | ₹239.81 Cr. | ₹248.45 Cr. | ₹357.20 Cr. | CostOfMaterialsConsumed |
| Purchases of Stock-in-Trade | ₹519.03 Cr. | ₹558.92 Cr. | ₹575.70 Cr. | ₹572.20 Cr. | PurchasesOfStockInTrade |
| Changes in Inventories | ₹-78.86 Cr. | ₹-74.55 Cr. | ₹-53.31 Cr. | ₹-63.72 Cr. | ChangesInInventoriesOfFinishedGoodsWorkInProgressAndStockInTrade |
| Employee Benefit Expense | ₹136.99 Cr. | ₹143.59 Cr. | ₹177.72 Cr. | ₹199.15 Cr. | EmployeeBenefitExpense |
| Finance Costs | ₹0.78 Cr. | ₹0.78 Cr. | ₹0.61 Cr. | ₹0.87 Cr. | FinanceCosts |
| Depreciation and Amortisation | ₹44.99 Cr. | ₹53.44 Cr. | ₹65.96 Cr. | ₹72.77 Cr. | DepreciationDepletionAndAmortisationExpense |
| Other Expenses | ₹225.47 Cr. | ₹274.89 Cr. | ₹341.98 Cr. | ₹361.51 Cr. | OtherExpenses |
| Total Expenses | ₹1,071.44 Cr. | ₹1,196.88 Cr. | ₹1,357.11 Cr. | ₹1,499.98 Cr. | Expenses |
| Profit Before Exceptional Items and Tax | ₹451.27 Cr. | ₹564.16 Cr. | ₹676.79 Cr. | ₹802.75 Cr. | ProfitBeforeExceptionalItemsAndTax |
| Exceptional Items | ₹0.08 Cr. | ₹0.27 Cr. | ₹0.00 Cr. | ₹0.04 Cr. | ExceptionalItemsBeforeTax |
| Profit Before Tax | ₹451.35 Cr. | ₹564.43 Cr. | ₹676.79 Cr. | ₹802.79 Cr. | ProfitBeforeTax |
| Tax Expense | ₹74.36 Cr. | ₹103.01 Cr. | ₹135.69 Cr. | ₹153.06 Cr. | TaxExpense |
| Net Profit (incl. minority interest) | ₹376.99 Cr. | ₹461.42 Cr. | ₹541.09 Cr. | ₹649.73 Cr. | ProfitLossForPeriod |
| Net Profit (to shareholders) | ₹376.26 Cr. | ₹457.08 Cr. | ₹563.38 Cr. | ₹641.24 Cr. | ProfitOrLossAttributableToOwnersOfParent |
| Basic EPS | ₹49.62 | ₹60.19 | ₹70.57 | ₹84.36 | BasicEarningsLossPerShareFromContinuingAndDiscontinuedOperations |
| Diluted EPS | ₹49.18 | ₹59.90 | ₹70.25 | ₹84.11 | DilutedEarningsLossPerShareFromContinuingAndDiscontinuedOperations |
Every figure above is the exact value of the named XBRL element from CAPLIPOINT.NS's cached filing for that year — nothing here is estimated or backfilled. A company shows one column per year StockProof actually has data for — never padded with blank years. Rows shown as N/A are genuinely not disclosed under that year's filing format (see peer comparison for how other Healthcare companies compare).